Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

Autor: Anna Latiano, M.R. D'Altilia, Giuseppe Corritore, Fabrizio Bossa, A. Marseglia, Sonia Carparelli, Francesca Tavano, Giuseppina Martino, Fulvia Terracciano, Anna Panza, Angelo Andriulli, M. Nardella, Maria Pastore, Francesco Perri, Orazio Palmieri, Michele Sacco, Maria Guerra, Tiziana Latiano
Rok vydání: 2020
Předmět:
Male
Antibodies
Viral
Inflammatory bowel disease
0302 clinical medicine
Crohn Disease
Seroepidemiologic Studies
skin and connective tissue diseases
Child
Aged
80 and over
Alimentary Tract
Gastroenterology
Antibodies
Monoclonal
Middle Aged
Ulcerative colitis
Thalidomide
Hospitalization
Italy
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
Female
Ustekinumab
Immunosuppressive Agents
medicine.drug
Biologic therapy
Adult
medicine.medical_specialty
Adolescent
IBD
Enzyme-Linked Immunosorbent Assay
Antibodies
Monoclonal
Humanized
Vedolizumab
COVID-19 Serological Testing
03 medical and health sciences
Young Adult
Gastrointestinal Agents
Internal medicine
medicine
Adalimumab
Humans
Risk factor
Aged
Biological Products
Hepatology
business.industry
SARS-CoV-2
COVID-19
medicine.disease
Inflammatory Bowel Diseases
Infliximab
Golimumab
Colitis
Ulcerative
business
Zdroj: Digestive and Liver Disease
ISSN: 1878-3562
Popis: Background Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs. Methods Information on demography, co-morbidities, clinical data regarding IBD, symptoms suggestive of the SARS-CoV-2 infection, close contacts with SARS-CoV-2 positive patients, hospitalization, and therapies administered for COVID-19 was collected for all patients who were being treated with biologic drugs. All patients underwent SARS-CoV-2 antibody testing. Results Two hundred and fifty-nine patients (27 children) with a mean age of 42.2 ± 16.7 years (range 9 - 88) and a mean duration of disease of 13.4 ± 10 years (range 0.2 – 49) were enrolled. One hundred four patients (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn's disease. About the therapy: 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two patients (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two patients resulted positive for IgG against SARS-CoV-2 (0.77%). Conclusions In patients with IBD, treatment with biologic drug does not represent a risk factor for the SARS-CoV-2 infection.
Databáze: OpenAIRE
Externí odkaz: